Eric Warren - 14 Mar 2022 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role
Chief Commercial Officer
Signature
/s/ Richard B. Bartram, by power of attorney
Issuer symbol
ESPR
Transactions as of
14 Mar 2022
Transactions value $
$0
Form type
4
Filing time
16 Mar 2022, 17:11:05 UTC
Previous filing
09 Mar 2022
Next filing
18 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ESPR Common Stock Award $0 +13K +31.63% $0.00 54.1K 14 Mar 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ESPR Stock Option (right to buy 57K 14 Mar 2022 Common Stock 57K $4.74 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The awards will vest quarterly over four years beginning on March 15, 2022.